These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 16390779)
1. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Garmes HM; Tambascia MA; Zantut-Wittmann DE Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779 [TBL] [Abstract][Full Text] [Related]
2. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion]. Wang A; Li M; Lu C Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662 [TBL] [Abstract][Full Text] [Related]
3. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168 [TBL] [Abstract][Full Text] [Related]
4. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA; Shin SY; Yoon BK; Choi D Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414 [TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Wu J; Zhu Y; Jiang Y; Cao Y Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522 [TBL] [Abstract][Full Text] [Related]
6. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Kazerooni T; Dehghan-Kooshkghazi M Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019 [TBL] [Abstract][Full Text] [Related]
7. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Romualdi D; Giuliani M; Draisci G; Costantini B; Cristello F; Lanzone A; Guido M Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978 [TBL] [Abstract][Full Text] [Related]
8. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894 [TBL] [Abstract][Full Text] [Related]
9. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Chou KH; von Eye Corleta H; Capp E; Spritzer PM Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of hyperandrogenism and hyperinsulinemia in PCOS patients with essential amino acids. A pilot clinical study]. Unfer V; Zacchè M; Serafini A; Redaelli A; Papaleo E Minerva Ginecol; 2008 Oct; 60(5):363-8. PubMed ID: 18854802 [TBL] [Abstract][Full Text] [Related]
11. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. Moran C; Renteria JL; Moran S; Herrera J; Gonzalez S; Bermudez JA Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993 [TBL] [Abstract][Full Text] [Related]
12. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572 [TBL] [Abstract][Full Text] [Related]
13. Glucose intolerance in Japanese patients with polycystic ovary syndrome. Kurioka H; Takahashi K; Miyazaki K Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071 [TBL] [Abstract][Full Text] [Related]
14. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Penna IA; Canella PR; Reis RM; Silva de Sá MF; Ferriani RA Hum Reprod; 2005 Sep; 20(9):2396-401. PubMed ID: 16006454 [TBL] [Abstract][Full Text] [Related]
15. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Nawrocka J; Starczewski A Gynecol Endocrinol; 2007 Apr; 23(4):231-7. PubMed ID: 17505944 [TBL] [Abstract][Full Text] [Related]
16. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528 [TBL] [Abstract][Full Text] [Related]
17. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
18. [Exploration of the classification of polycystic ovarian syndrome]. Lin JF; Li X; Zhu MW Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924 [TBL] [Abstract][Full Text] [Related]
19. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome]. Liang X; Zhuang G; Fan Q Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926 [TBL] [Abstract][Full Text] [Related]
20. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]